Roy Herbst
Overview
Explore the profile of Roy Herbst including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
2666
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kamle S, Ma B, Schor G, Bailey M, Pham B, Cho I, et al.
Transl Oncol
. 2024 Aug;
49:102108.
PMID: 39178575
Non-small cell lung cancer (NSCLC) accounts for 85 % of all lung cancers. In NSCLC, 10-20 % of Caucasian patients and 30-50 % of Asian patients have tumors with activating...
2.
Neal J, Minichiello K, Brennick R, Huang R, Hiemenz M, Amler C, et al.
Oncologist
. 2024 Apr;
29(6):e843-e847.
PMID: 38597608
For cancer clinical trials that require central confirmation of tumor genomic profiling, exhaustion of tissue from standard-of-care testing may prevent enrollment. For Lung-MAP, a master protocol that requires results from...
3.
Fernandez A, Gavrielatou N, McCann L, Shafi S, Moutafi M, Martinez-Morilla S, et al.
J Thorac Oncol
. 2022 Jun;
17(9):1078-1085.
PMID: 35764237
Introduction: Immune checkpoint inhibitors (ICIs) have become standard of care in lung cancer management, but only a relatively small percentage of patients treated respond. Current predictive biomarkers, including immunohistochemical detection...
4.
Remon J, Lacas B, Herbst R, Reck M, Garon E, Scagliotti G, et al.
Eur J Cancer
. 2022 Mar;
166:112-125.
PMID: 35286903
Background: Now that immunotherapy plus chemotherapy (CT) is one standard option in first-line treatment of advanced non-small cell lung cancer (NSCLC), there exists a medical need to assess the efficacy...
5.
Joel M, Umrao S, Chang E, Choi R, Yang D, Duncan J, et al.
JCO Clin Cancer Inform
. 2022 Mar;
6:e2100170.
PMID: 35271304
Purpose: Deep learning (DL) models have rapidly become a popular and cost-effective tool for image classification within oncology. A major limitation of DL models is their vulnerability to adversarial images,...
6.
Herbst R, Jassem J, Abogunrin S, James D, McCool R, Belleli R, et al.
Front Oncol
. 2021 Jul;
11:676732.
PMID: 34307144
In the absence of head-to-head trials of first-line treatments for metastatic non-small cell lung cancer (NSCLC), synthesis of available evidence is needed. We conducted a systematic literature review and network...
7.
Lucas C, Wong P, Klein J, Castro T, Silva J, Sundaram M, et al.
Nature
. 2020 Jul;
584(7821):463-469.
PMID: 32717743
Recent studies have provided insights into the pathogenesis of coronavirus disease 2019 (COVID-19). However, the longitudinal immunological correlates of disease outcome remain unclear. Here we serially analysed immune responses in...
8.
Reuben A, Zhang J, Chiou S, Gittelman R, Li J, Lee W, et al.
Nat Commun
. 2020 Feb;
11(1):603.
PMID: 32001676
Immunotherapy targeting T cells is increasingly utilized to treat solid tumors including non-small cell lung cancer (NSCLC). This requires a better understanding of the T cells in the lungs of...
9.
Nilsson M, Sun H, Diao L, Tong P, Liu D, Li L, et al.
Sci Transl Med
. 2017 Nov;
9(415).
PMID: 29118262
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance mediated by T790M-independent mechanisms remains a major challenge in the treatment of non-small cell lung cancer (NSCLC). We identified a...
10.
Waqar S, Bonomi P, Govindan R, Hirsch F, Riely G, Papadimitrakopoulou V, et al.
J Thorac Oncol
. 2016 Jul;
11(9):1387-96.
PMID: 27401214
Recent advances in molecularly targeted therapy and immunotherapy offer a glimmer of hope for potentially realizing the dream of personalized therapy for lung cancer. This article highlights current questions in...